Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$6.07 billion
P/E Ratio
125.97
Dividend Yield
0.00%
Shares Outstanding
339.78 million
Earnings per share
0.099
Dividend per share
N/A
Year To Date Return
55.80%
Earnings Yield
0.79%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals Ltd (ASX: TLX)
Latest News
Healthcare Shares
Forget CSL shares, I'd buy this ASX biotech stock instead
Healthcare Shares
4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown
Healthcare Shares
Are Telix shares a buy after its big US FDA news?
Healthcare Shares
These 2 ASX healthcare shares just jumped up to 15%. Here's why
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
Buy, hold, sell: Domino's Pizza, Telix Pharmaceuticals, Westfarmers shares
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
Why are Telix Pharmaceuticals shares charging higher today?
Healthcare Shares
Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug
Healthcare Shares
Forget CSL shares. 3 ASX healthcare stocks with bigger upside
Healthcare Shares
CSL led the ASX healthcare shares rebound. Can it continue?
Broker Notes
4 high conviction ASX stock picks from Canaccord Genuity
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
TLX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | $17.85 | $0.40 | 2.29% | 3,062,365 | $17.57 | $18.11 | $17.51 |
| 17 Sep 2026 | $17.45 | $0.58 | 3.44% | 2,277,535 | $16.87 | $17.83 | $16.68 |
| 16 Sep 2026 | $16.87 | $-0.88 | -4.96% | 3,613,622 | $17.55 | $17.74 | $16.48 |
| 15 Sep 2026 | $17.75 | $1.41 | 8.63% | 6,277,577 | $16.80 | $18.22 | $16.70 |
| 14 Sep 2026 | $16.34 | $0.67 | 4.28% | 4,723,800 | $17.50 | $17.65 | $15.85 |
| 11 Sep 2026 | $15.67 | $-1.09 | -6.50% | 2,193,327 | $16.45 | $16.61 | $15.50 |
| 10 Sep 2026 | $16.76 | $0.07 | 0.42% | 1,759,963 | $16.80 | $17.00 | $16.64 |
| 09 Sep 2026 | $16.69 | $0.19 | 1.15% | 1,109,874 | $16.43 | $16.77 | $16.28 |
| 08 Sep 2026 | $16.50 | $0.25 | 1.54% | 1,119,678 | $16.16 | $16.59 | $15.97 |
| 07 Sep 2026 | $16.25 | $-0.22 | -1.34% | 1,122,950 | $16.20 | $16.50 | $15.93 |
| 04 Sep 2026 | $16.47 | $0.21 | 1.29% | 1,527,242 | $16.35 | $16.66 | $16.26 |
| 03 Sep 2026 | $16.26 | $0.57 | 3.63% | 2,058,883 | $15.86 | $16.51 | $15.50 |
| 02 Sep 2026 | $15.69 | $0.42 | 2.75% | 1,568,691 | $15.30 | $16.00 | $15.08 |
| 01 Sep 2026 | $15.27 | $-0.09 | -0.59% | 1,638,595 | $15.22 | $15.30 | $14.86 |
| 31 Aug 2026 | $15.36 | $-0.29 | -1.85% | 1,092,733 | $15.39 | $15.59 | $15.26 |
| 28 Aug 2026 | $15.65 | $0.07 | 0.45% | 985,671 | $15.66 | $16.15 | $15.62 |
| 27 Aug 2026 | $15.58 | $0.09 | 0.58% | 1,273,984 | $15.40 | $15.84 | $15.17 |
| 26 Aug 2026 | $15.49 | $-0.67 | -4.15% | 1,504,493 | $16.23 | $16.52 | $15.44 |
| 25 Aug 2026 | $16.16 | $0.00 | 0.00% | 995,818 | $16.18 | $16.25 | $15.91 |
| 24 Aug 2026 | $16.16 | $0.54 | 3.46% | 1,683,785 | $15.50 | $16.39 | $15.20 |
| 21 Aug 2026 | $15.62 | $-1.76 | -10.13% | 4,587,381 | $16.62 | $16.76 | $15.62 |
| 20 Aug 2026 | $17.38 | $0.54 | 3.21% | 5,205,523 | $17.15 | $18.13 | $16.55 |
| 19 Aug 2026 | $16.84 | $0.08 | 0.48% | 974,002 | $16.76 | $17.15 | $16.73 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Jun 2026 | David Gill | Buy | 10,200 | $96,221 |
On-market trade. 10,200 ADS, US$9.4335 per share
|
| 26 May 2026 | Maria Rivas | Issued | 21,597 | $285,728 |
Issue of securities. The notional exercise price is US$9.47, 21,597 SARs
|
| 26 May 2026 | William (Bill) Jellison | Issued | 21,597 | $285,728 |
Issue of securities. The notional exercise price is US$9.47. 21,597 SARs
|
| 26 May 2026 | Christian Behrenbruch | Issued | 366,966 | $4,854,960 |
Issue of securities. 873,418 rights
|
| 26 May 2026 | David Gill | Issued | 30,048 | $397,535 |
Issue of securities. 30,048 SARs, The notional exercise price is US$9.47
|
| 26 May 2026 | Marie McDonald | Issued | 23,139 | $306,128 |
Issue of securities. 23,139 SARs, The notional exercise price is $13.43
|
| 29 Apr 2026 | Christian Behrenbruch | Buy | 67,935 | $996,699 |
On-market trade.
|
| 16 Mar 2026 | Christian Behrenbruch | Expiry | 20,045 | $220,094 |
As advised by the company. 506,452 rights
|
| 05 Nov 2025 | Christian Behrenbruch | Exercise | 100,708 | $441,101 |
Exercise of options. Cash consideration
|
| 05 Nov 2025 | Christian Behrenbruch | Issued | 100,708 | $441,101 |
Exercise of options. Cash consideration
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Jann E Skinner | Non-Executive Director | Jun 2018 |
Ms Skinner was a partner at PricewaterhouseCoopers from 1987 to 2004. She has served as Chair of Create Foundation Limited since July 2024 and Director since 2004. She also served as Non-Executive Director of QBE Insurance Group Limited from October 2014 to May 2024 and Director of HSBC Bank Australia Limited from April 2017 to April 2023. She is Chair of Risk Committee and member of people committee.
|
| Ms Marie Elizabeth McDonald | Non-Executive Director | Mar 2025 |
Ms McDonald serves as a Non-Executive Director of Nanosonics Limited (since October 2016), Walter and Eliza Hall Institute of Medical Research (since October 2016) and Nufarm Limited (since March 2017) and served as a Non-Executive Director of CSL Limited between August 2013 and October 2025. She is member of the Risk Committee and Chair of People Committee.
|
| Dr Christian Peter Behrenbruch | Chief Executive OfficerManaging Director | Jan 2017 |
Dr Behrenbruch has previously served as Chief Executive Officer at Mirada Solutions from July 2001 to December 2002, President at CTI Molecular Imaging (now Siemens Healthcare) from August 2003 to September 2006, Chief Executive Officer at Fibron Technologies, Inc. from June 2008 to December 2011 and Chief Executive Officer at ImaginAb, Inc from October 2007 to February 2015.
|
| Dr Mark Alexander Nelson | Non-Executive Director | Sep 2017 |
Dr Nelson has served as Chairman of the Caledonia Investments Group since January 2012, and as a Director of The Caledonia Foundation since August 2002. He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group from February 1992 to January 2012. He has also served as Director of Kaldor Public Art Projects since October 2005, Governor of the Florey Neurosciences Institute since October 2007, Director of the Mindgardens Neuroscience Network since February 2018 and Chairman of Art Exhibitions Australia since 2019. He is member of Risk Committee and People Committee.
|
| Mr David Gill | Non-Executive DirectorNon-Executive Chairman | May 2026 |
Mr. Gill is a life sciences executive with 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical. Mr. Gill serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life
Ltd, RapidPulse Inc., and huMannity Medtec. |
| Dr Maria Rivas | Non-Executive Director | May 2026 |
Dr Rivas is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company, and also served as an independent director for Medidata (NASDAQ: MDSO) from 2018-2019 until its merger with Dassault Systemes. Dr. Rivas spent over 25 years in healthcare developing and commercializing medical devices and pharmaceutical products across multiple therapeutic areas including oncology, rare diseases and neurosciences, most recently as Chief Medical Officer at Pfizer, Inc. (NYSE: PFE). She has managed global operations of several thousand data scientists, healthcare experts and field staff, and overseen the launch of multiple blockbuster medical products.
|
| Mr William (Bill) Jellison | Non-Executive Director | May 2026 |
Mr Jellison is a public company director and corporate finance leader with over 30 years' experience, including audit committee leadership in regulated operating environments. He currently serves on the board of directors of Medtronic plc (NYSE: MDT), Anika Therapeutics, Inc. (NASDAQ: ANIK), Avient Corporation (NYSE: AVNT), Solenis LLC, and Young Innovations, Inc., and until recently served as a director of Masimo Corporation (NASDAQ: MASI). During his executive career, Mr. Jellison recently served as Vice President and CFO of Stryker Corporation (NYSE: SYK), overseeing international finance, SEC reporting, mergers and acquisitions, and capital allocation.
|
| Mr Shomalin Naidoo | Interim Company Secretary | Apr 2026 |
-
|
| Raphael Ortiz | Chief Executive Officer Telix International |
-
|
|
| Kevin Richardson | Chief Executive Officer Telix Precision Medicine |
-
|
|
| Richard Valeix | Chief Executive Officer Telix Therapeutics |
-
|
|
| Darren Smith | Group Chief Financial Officer |
-
|
|
| David Cade | Group Chief Medical Officer |
-
|
|
| Mary Jessel | Group Chief of Clinical Affairs |
-
|
|
| Darren Patti | Group Chief Operating Officer |
-
|
|
| Lena Moran-Adams | Group General Counsel |
-
|
|
| Shomalin Naidoo | Interim Company Secretary |
-
|
|
| Meredith Crowe | Senior Vice President People & Culture |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 53,462,930 | 15.80% |
| Citicorp Nominees Pty Limited | 31,693,330 | 9.40% |
| J P Morgan Nominees Australia Pty Limited | 24,921,869 | 7.40% |
| Gnosis Verwaltungsgesellschaft Mbh | 20,675,000 | 6.10% |
| ELK River Holdings Pty Ltd | 20,675,000 | 6.10% |
| BNP Paribas Nominees Pty Ltd | 15,376,442 | 4.50% |
| BNP Paribas Noms Pty Ltd | 10,433,812 | 3.10% |
| Grand Decade Developments Limited | 6,000,000 | 1.80% |
| BNP Paribas Nominees Pty Ltd i | 5,643,043 | 1.70% |
| UV Cap Gmbh and Co Kg | 4,878,261 | 1.40% |
| Merrill Lynch (Australia) Nominees Pty Limited | 3,294,701 | 1.00% |
| Man Holdings Pty Ltd | 3,228,750 | 1.00% |
| BNP Paribas Nominees Pty Ltd ii | 2,923,857 | 0.90% |
| BNP Paribas Noms (Nz) Ltd | 2,714,023 | 0.80% |
| Netwealth Investments Limited | 2,406,576 | 0.70% |
| Lightpoint Medical Ltd | 1,918,112 | 0.60% |
| The Oncidium Foundation | 1,846,582 | 0.60% |
| Pacific Custodians Pty Limited | 1,618,200 | 0.50% |
| Ubs Nominees Pty Ltd | 1,191,214 | 0.40% |
| WHSP Holdings Pty Limited | 1,136,783 | 0.30% |
| BNP Paribas Nominees Pty Ltd iii | 1,120,510 | 0.30% |
